Authors

Deciding When to Defer Oncology Treatment

Oncologists are challenged to make a different determination when a new patient presents with advanced cancer.

Robert L. Ferris, MD, PhD, Appointed Executive Director of UNC Lineberger Comprehensive Cancer Center

Robert L. Ferris, MD, PhD, has been named the executive director of UNC Lineberger Comprehensive Cancer Center and UNC system chief of oncology services.

ACCC Releases Trending Now in Cancer Care

The Association of Community Cancer Centers today released its annual Trending Now in Cancer Care report, including actionable strategies in 8 key areas.

The Microbiome and Colon Cancer: Dietary Influence on Incidence, Morbidity, and Mortality

One of the prime risk factors for CRC is the consumption of a high-risk, Western-style diet high in processed foods, refined grains, red meat, and sugar.

Carbone Partner Perspectives: Alcohol: The Carcinogen We’re Not Talking About

Despite alarming figures and trends, public awareness of alcohol as a carcinogen remains low.

McKesson’s Practice Insights Designated as a 2024 Qualified Clinical Data Registry by Centers for Medicare & Medicaid Services

McKesson has received approval from the CMS to participate in the Merit-based Incentive Payment System as a Qualified Clinical Data Registry.

Cancer Treatment Centers of America Grows Medical Oncologist Roster Across Hospitals

Medical oncologists Dr. Ajaz Khan, Dr. Ryan Engel, and Dr. Nitika Sharma are the latest board-certified, fellowship-trained physicians who have chosen to practice medicine at Cancer Treatment Centers of America®.

The Future of Reimbursement: How AI Can Revolutionize Oncology Practices

By retrospectively analyzing health care financial data and using the intelligence generated to guide future claims to a more successful outcome, machine learning platforms may reduce the need for repeated insurance submissions and appeals and can improve the practice’s clean claim rate.

EXPLORER Shrinks the Time it Takes for Imaging to Spot Cancer

Cancer parametric PET imaging with radioactive tracers is reduced from an hour to 20 minutes

McKesson's Patient-Reported Outcomes Measure Will Track Improvements in Health-Related Social Needs

The use of patient-reported outcome measures—the gold standard in quality measurement—is crucial to building a patient-centered, value-based care system.

Long-Term Survivors of Childhood Cancer at Higher Risk of Death Following Heart Issues; Threshold for Treating Risk Factors Should Be Lower

Survivors of childhood cancer are at a significantly higher risk of death following a major cardiovascular event than the general public.

Additional Biomarkers Are Needed to Inform ADC Selection in NSCLC

Benjamin P. Levy, MD, discusses advances with ADCs in lung cancer during the 20th Annual New York Lung Cancers Symposium.

From the Top: An Oncologist's Perspective on Advances in Locally Advanced Head and Neck Squamous Cell Carcinoma

The US Oncology Network Highlights Success With Oncology Care Model

Practices participating in the Oncology Care Model, an experimental payment model developed by the Center for Medicare and Medicaid Innovation, are incentivized to improve patient experiences and outcomes by providing enhanced services and care while bending the total cost curve.

Ovarian Cancer Prevention With the Opportunistic Salpingectomy: An Opportunity for Multidisciplinary Collaboration

A new understanding of pathogenesis has given rise to a promising prevention strategy for women at an average risk of developing ovarian cancer through surgical removal of the fallopian tubes, referred to as an opportunistic salpingectomy.

Designer DNA Therapeutic Wipes Out Cancer Stem Cells, Treats Multiple Myeloma in Mice

Study supports launch of Phase I clinical trial to test a designer DNA agent — an antisense oligonucleotide that targets a gene called IRF4 — in patients with multiple myeloma

Sacituzumab Govitecan Plus Pembrolizumab Yields Predictable, Manageable Safety Profile in TNBC

Sacituzumab govitecan combined with pembrolizumab showed a manageable safety profile with lower TEAE discontinuation rates in TNBC.

Second-Line Axi-Cel Offers a “Practice-Changing” Indication for LBCL

Lori A. Leslie, MD, reviews how the approval of axicabtagene ciloleucel may impact or enhance current practice patterns for adult patients with large B-cell lymphoma.

Developing Culturally Concordant Palliative Care for Hindu Patients and Families

Sometimes, clinicians do not acknowledge how patients' values and beliefs influence how they ascribe meaning to their illness, how they prefer to receive information, and how they make decisions until the end-of-life stage, leading to misunderstandings between clinicians and patients.

Adjuvant Nivolumab Does Not Provide DFS Advantage in Localized, High-Risk RCC

Adjuvant nivolumab monotherapy did not yield a disease-free survival benefit vs placebo in patients with localized renal cell carcinoma.

Breaking New Ground in Childhood Cancer

Accelerating progress in childhood cancer faces three main obstacles: funding, drugs, and family support.

Exploring the Nuances of Postoperative Considerations in Pancreatic Cancer

Zyed Nabeel Zafar, MD, MPH, explores the nuances of postoperative considerations in pancreatic cancer treatment.

Clinical Updates for the Management of Lung Cancer Brain Metastases

As improved cancer therapies are helping patients live longer, the safe and effective management of lung cancer brain metastases is coming to the fore.

Personalization Is Key to Successful Mentorship

Linda Hasunuma, PhD, highlights the importance of empathy and support as it relates to mentorship, as well as advice for establishing a successful fellowship program and communication strategies.

Talquetamab-Based Triplet Elicits Deep Responses in R/R Myeloma

Talquetamab plus daratumumab yields improved patient outcomes in patients with relapsed/refractory multiple myeloma.

Mobile Health Intervention Improves QOL in AYA Breast Cancer Survivors

A mobile health intervention was associated with improvements to general and cancer-specific quality of life in AYA breast cancer survivors.

Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma

CARTITUDE-4 data show heterogeneous outcomes with cilta-cel after progression on bridging therapy in relapsed/refractory multiple myeloma.

Oncology Providers Face Rising Pressures From Payers Over Therapy Choices

Insurance companies are beginning to indirectly manage prescribing to better manage costs.

Experimental Drug Could Spur Immunotherapy Response in Patients With Non–Small Cell Lung Cancer

Research led by UT Southwestern scientists suggests that an investigational drug could restore the ability of some non–small cell lung cancers to respond to an immune checkpoint blockade, a therapy that harnesses the immune system to fight malignant tumors.

Digital Health and Process Improvements Enhance Community-Based Patient Care

A marked reduction in hospitalizations and emergency department visits are key metrics for value-based care programs. Quality improvement processes and electronic patient management systems may give practices a way to fully embrace these programs and remain mindful of cost while ensuring that patients receive high-quality care.